Get the Stockscreener App
0.403
2.52%
0.0099
After Hours:
.41
0.007
+1.74%
Vivos Therapeutics Inc stock is traded at $0.403, with a volume of 131.13K.
It is up +2.52% in the last 24 hours and down -9.96% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$0.3931
Open:
$0.417
24h Volume:
131.13K
Relative Volume:
0.09
Market Cap:
$5.60M
Revenue:
$19.57M
Net Income/Loss:
$-25.12M
P/E Ratio:
-0.1744
EPS:
-2.3114
Net Cash Flow:
$-19.71M
1W Performance:
-1.99%
1M Performance:
-9.96%
6M Performance:
-77.49%
1Y Performance:
-92.31%
1-Day Range:
$0.3864
$0.417
1-Week Range:
$0.3637
$0.4199
52-Week Range:
$0.3637
$5.6899
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.403 | 5.46M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
TradingKey - TradingKey
Vivos Therapeutics Inc (VVOS) Cash Flow - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.393|Chg%:+0.003 - TradingKey
VVOS|Vivos Therapeutics Inc|Price:0.395|Chg%:+0.002 - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics (VVOS) Holds Near Support as Micro-Cap Stock Shows Measured MovementVolatility Breakout Picks - dars.gov.et
Vivos Therapeutics (VVOS) Edges Higher, Testing Key Resistance Near $0.44Dynamic Hedging - dars.gov.et
Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts - Yahoo Finance
Vivos Therapeutics (VVOS) Holds Steady at $0.41, Support Level in FocusFear Greed Index - dars.gov.et
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake - TradingView
Investor group takes 19.9% position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics (NASDAQ: VVOS) insider entity buys 5.5M derivatives - Stock Titan
Vivos Therapeutics (NASDAQ: VVOS) holder discloses warrant and preferred stake - Stock Titan
Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Vivos Therapeutics (VVOS) Slides 6.87% as Bearish Pressure Tests Critical SupportLate Stage Breakouts - DonanımHaber
A. G. P. Maintains Vivos Therapeutics(VVOS.US) With Hold Rating, Cuts Target Price to $0.75 - Moomoo
Vivos Therapeutics Announces Securities Purchase Agreement and Registration Rights for PIPE Financing - Minichart
Vivos Therapeutics Creates New Series A Preferred Stock - TipRanks
Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital - TradingView
Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants - Stock Titan
Vivos Therapeutics (VVOS) Holds Near Support Amid Modest Decline – Key Levels in FocusMFI Overbought - dars.gov.et
Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
VVOSVivos Therapeutics Inc Latest SEC Filings - Finviz
Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market SessionAlzamend Neuro (NASDAQ:ALZN), Vivos Ther - Benzinga
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants - The Manila Times
Vivos Therapeutics, Inc. announced that it has received $1 million in funding - marketscreener.com
VIVOS THERAPEUTICS INC (VVOS) Stock Chart - ChartMill
Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS) - TradingView
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline - TipRanks
Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact - Stock Titan
Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville - TradingView
VVOS Forecast — Price Target — Prediction for 2027 - TradingView
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
VVOS Q1 2026 Earnings: EPS Misses Estimates as Stock Surges on Operational ProgressOne-Time Gain Impact - Bölüm Sonu Canavarı
Vivos extends debt conversion deadline with Streeterville to August - Investing.com UK
Vivos extends debt conversion deadline with Streeterville to August By Investing.com - Investing.com Australia
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity - marketscreener.com
Vivos gets more time to convert $4.5M debt into equity - Stock Titan
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics (VVOS) Slides 6% as Selling Pressure Intensifies Near Key SupportSystematic Flow - dars.gov.et
Vivos Therapeutics Plans Rights Offering to Existing Shareholders - TipRanks
Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms - Stock Titan
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):